Mr. Shkreli went to Washington Thursday morning to testify at the House Oversight and Government Reform Committee hearing on drug pricing. But former Turing Pharmaceuticals and KaloBios CEO Martin Shkreli invoked his Fifth Amendment right not to incriminate himself.
Shkreli may not have spoken much, but, as they say, a picture tells 1,000 words.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Did he seem uncomfortable during his swearing-in?
Or was the notorious pharma dudebro, Wu-Tang Clan fan and future movie subject trying to project the confidence that so often has veered into arrogance since he became the poster child for runaway price hikes last year?
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Maybe he was just checking out the grandeur of the surroundings?
Or listening intently to the questioning?
He did actually speak, though not much on substance.
That’s attorney Benjamin Brafman whispering instructions to his client.
One who did answer questions was current Turing Chief Commercial Officer Nancy Retzlaff. To the left is Howard Schiller, interim CEO of Valeant Pharmaceuticals, another drug company under fire for its aggressive pricing.
Afterwards, Shkreli ran out and tried to get into the wrong car.
Photos: Mark Wilson/Getty Images